Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer
Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.
Pancreatic Cancer
BIOLOGICAL: G17DT
Patient Survival, The vital status of each patient was followed until death or end of the study., Up to week 134|Number of Participants with Serious and Non-Serious Adverse Events, Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-exisiting illnesses, were assessed at each visit., up to week 134
Objective tumor response, Patients were monitored for an objective tumor response measured by means of an abdomincal computed tomography., Weeks 24 and 52
Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.